Overjet, which creates AI-based software for dental clinics, raises $27M Series A led by General Catalyst, Insight Partners; its tech recently got FDA clearance
After cutting its teeth automating the dental insurance claims process, Overjet is now ready to expand its artificial intelligence software …
Context & Ripple Effects
Overjet's arc starts in claims paperwork: the company built its reputation automating the dental insurance claims process before turning the same imaging AI toward disease identification, and this $27M round lands right after [[a:fda-clearance-placeholder|FDA clearance]] gave the diagnostic product a regulated stamp of approval.
General Catalyst and Insight Partners treated this Series A as an entry position, not a one-off — both firms led again in Overjet's $42.5M Series B at a $425M valuation four months later and its $53.2M Series C at $550M in 2024, making this round the first data point in a sustained thesis on dental AI.
First-order effects
- Overjet gets the capital to push beyond claims automation into AI-assisted diagnosis from dental scans, with FDA clearance letting it sell clinical decision support rather than just back-office tooling.
- General Catalyst and Insight Partners secure early positions in a company whose valuations climb from this round through a $550M Series C, validating their repeat-backer strategy.
Second-order effects
- Practice-analytics incumbents like Dental Intelligence, which raised $34M in 2019 on workflow automation, now compete against an AI that reads the clinical image itself rather than just the schedule.
- Insurers sit on the other side of Overjet's original product — the same claims pipeline it automated becomes the channel where payer-side AI like Beam Dental's hygiene-rewards model meets clinic-side diagnostics.
Third-order effects
- Dental AI splits into two funded lanes — cleared diagnostic imaging and administrative automation, the latter still attracting first-time institutional money years later via Lassie's $35M raise — with regulatory clearance acting as the moat separating them.
- If the pattern of backer continuity holds, specialist AI companies in narrow clinical verticals consolidate around small groups of generalist funds willing to fund across every stage.
The trend: Vertical AI in healthcare is moving from single-task automation toward regulator-cleared diagnostic platforms, with the same lead investors compounding their positions across successive rounds.